姜黄素类药物治疗代谢相关脂肪性肝病的研究进展  

Advances in the Treatment of Metabolism-related Fatty Liver Disease with Curcumin-based Drugs

作　　者：孙子林 肖爽 彭明利[1] SUN Zilin;XIAO Shuang;PENG Mingli(Key Laboratory of Molecular Biology of Infectious Diseases,Ministry of Education/Institute of Viral Hepatitis,Chongqing Medical University/Department of Infection,The Second Hospital of Chongqing Medical University,Chongqing 400010,China)

机构地区：[1]教育部感染性疾病分子生物学重点实验室,重庆医科大学病毒性肝炎研究所,重庆医科大学附属第二医院感染科,重庆400010

出　　处：《中国现代应用药学》2023年第7期1001-1008,共8页Chinese Journal of Modern Applied Pharmacy

摘　　要：近年来代谢相关脂肪性肝病(metabolic-associated fatty liver disease,MAFLD)的发病率逐年增加,已成为威胁人类健康的最常见的慢性肝病,目前临床上尚没有治疗MAFLD的有效药被批准使用。多项体内外研究证实姜黄素可通过影响脂肪酸代谢、胰岛素抵抗、肝脏炎症及肠道菌群进程来改善MAFLD。本文总结了近5年来姜黄素类药物治疗MAFLD在动物实验和临床研究中的进展,以期为姜黄素类药物治疗代谢类相关疾病提供更多可能。The incidence of metabolic-associated fatty liver disease(MAFLD)has been increasing year by year in recent years and has become the most common chronic liver disease threatening human health,and there are no clinically effective drugs approved for the treatment of MAFLD.Several in vitro and in vivo studies have demonstrated that curcumin may improve MAFLD by affecting fatty acid metabolism,insulin resistance,liver inflammation,and intestinal flora processes.This paper summarizes the progress of curcumin-based drugs for MAFLD in animal studies and clinical studies in the past 5 years,with the aim of providing more possibilities for curcumin-based drugs for the treatment of metabolic-related diseases.

关 键 词：代谢相关脂肪性肝病 姜黄素 脂肪酸代谢 胰岛素抵抗 肠道菌群 

分 类 号：R285[医药卫生—中药学]